Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck.
Head and Neck Neoplasms
Immunotherapy
Ipilimumab
Nivolumab
Radiotherapy
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
accepted:
16
07
2023
medline:
7
8
2023
pubmed:
4
8
2023
entrez:
3
8
2023
Statut:
ppublish
Résumé
The combination of nivolumab and ipilimumab has been approved for the treatment of multiple solid tumors. This was a phase I study investigating definitive radioimmunotherapy (RIT) with nivolumab and ipilimumab for the treatment of locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). Patients with newly diagnosed, stage IVA-IVB SCCHN eligible for cisplatin-based chemotherapy received nivolumab (3 mg/kg every 2 weeks for a total of 17 doses) and ipilimumab (1 mg/kg every 6 weeks for a total of 6 doses) starting 2 weeks prior to radiotherapy. The primary endpoint was safety of definitive RIT. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Exploratory endpoints included the association of baseline programmed death-ligand 1 (PD-L1) expression as well as on-treatment changes in immune bias with treatment outcomes. Twenty-four patients were enrolled. With a median follow-up of 36.1 months, grade 3 or higher treatment-related adverse events were reported in 21 individuals (88%); 5 individuals developed in-field soft tissue ulceration during consolidation immunotherapy, resulting in one fatality. The 3-year PFS and OS rates were 74% (95% CI 58% to 94%) and 96% (95% CI 88% to 100%), respectively. PD-L1 combined positive score (CPS) did not correlate with death or disease progression. Decreases in extracellular vesicle PD-L1 within the concurrent RIT phase were associated with prolonged PFS (p=0.006). Also, interval decreases in circulating interleukin (IL)4, IL9, IL12, and IL17a during concurrent RIT were associated with subsequent ulceration. Definitive RIT with nivolumab and ipilimumab has sufficient clinical activity to support further development. Early changes in circulating biomarkers appear able to predict treatment outcomes as well as ensuing in-field soft tissue ulceration. NCT03162731.
Sections du résumé
BACKGROUND
The combination of nivolumab and ipilimumab has been approved for the treatment of multiple solid tumors. This was a phase I study investigating definitive radioimmunotherapy (RIT) with nivolumab and ipilimumab for the treatment of locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN).
METHODS
Patients with newly diagnosed, stage IVA-IVB SCCHN eligible for cisplatin-based chemotherapy received nivolumab (3 mg/kg every 2 weeks for a total of 17 doses) and ipilimumab (1 mg/kg every 6 weeks for a total of 6 doses) starting 2 weeks prior to radiotherapy. The primary endpoint was safety of definitive RIT. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Exploratory endpoints included the association of baseline programmed death-ligand 1 (PD-L1) expression as well as on-treatment changes in immune bias with treatment outcomes.
RESULTS
Twenty-four patients were enrolled. With a median follow-up of 36.1 months, grade 3 or higher treatment-related adverse events were reported in 21 individuals (88%); 5 individuals developed in-field soft tissue ulceration during consolidation immunotherapy, resulting in one fatality. The 3-year PFS and OS rates were 74% (95% CI 58% to 94%) and 96% (95% CI 88% to 100%), respectively. PD-L1 combined positive score (CPS) did not correlate with death or disease progression. Decreases in extracellular vesicle PD-L1 within the concurrent RIT phase were associated with prolonged PFS (p=0.006). Also, interval decreases in circulating interleukin (IL)4, IL9, IL12, and IL17a during concurrent RIT were associated with subsequent ulceration.
CONCLUSIONS
Definitive RIT with nivolumab and ipilimumab has sufficient clinical activity to support further development. Early changes in circulating biomarkers appear able to predict treatment outcomes as well as ensuing in-field soft tissue ulceration.
TRIAL REGISTRATION NUMBER
NCT03162731.
Identifiants
pubmed: 37536941
pii: jitc-2023-007141
doi: 10.1136/jitc-2023-007141
pmc: PMC10401226
pii:
doi:
Substances chimiques
Nivolumab
31YO63LBSN
Ipilimumab
0
B7-H1 Antigen
0
Banques de données
ClinicalTrials.gov
['NCT03162731']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA056036
Pays : United States
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Radiother Oncol. 2020 Mar;144:209-217
pubmed: 32044419
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Int J Radiat Oncol Biol Phys. 2023 Apr 3;:
pubmed: 37019367
Nat Commun. 2021 Dec 22;12(1):7348
pubmed: 34937871
J Clin Oncol. 2006 Dec 20;24(36):5630-6
pubmed: 17179101
J Clin Oncol. 2018 Jun 7;:JCO2017762518
pubmed: 29878867
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
J Clin Oncol. 2004 Jan 1;22(1):69-76
pubmed: 14657228
Nature. 2015 Apr 16;520(7547):373-7
pubmed: 25754329
JAMA Oncol. 2020 Oct 1;6(10):1563-1570
pubmed: 32852531
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
Cancer Treat Rev. 2021 Jun;97:102192
pubmed: 33819755
Front Oncol. 2019 Mar 06;9:122
pubmed: 30895168
Cell. 2019 Apr 4;177(2):414-427.e13
pubmed: 30951669
J Immunother Cancer. 2021 Jan;9(1):
pubmed: 33472857
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12885-90
pubmed: 19433802
Lancet. 2019 Jan 5;393(10166):40-50
pubmed: 30449625
Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1198-205
pubmed: 22749632
Lancet Oncol. 2021 Apr;22(4):450-462
pubmed: 33794205
Radiother Oncol. 2021 Mar;156:281-293
pubmed: 33515668
J Immunother Cancer. 2022 Jan;10(1):
pubmed: 35078923
Ann Oncol. 2022 May;33(5):488-499
pubmed: 35124183
Immunity. 2010 May 28;32(5):593-604
pubmed: 20510870
Lancet. 2008 May 17;371(9625):1695-709
pubmed: 18486742
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Ann Oncol. 2012 Sep;23 Suppl 10:x173-7
pubmed: 22987957
N Engl J Med. 2004 May 6;350(19):1937-44
pubmed: 15128893
Cytokine. 2015 Sep;75(1):89-116
pubmed: 26255210
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33023982
Lancet. 2019 Jan 5;393(10166):51-60
pubmed: 30449623